

# SCIENTIFIC AND REGULATORY CONSIDERATIONS FOR ASSESSMENT OF IMMUNOGENICITY RISK FOR GENERIC PEPTIDE AND OLIGONUCLEOTIDE DRUG PRODUCTS

## Session 5: Synthetic Oligonucleotide Therapeutics

### *Introduction and Moderator:*

**Deyi Zhang, PhD**

Senior Chemist, DTP I, ORS, OGD, CDER, FDA

### *Presenters and Panelists:*

**Markham C. Luke, MD, PhD**

Director, DTP I, ORS, OGD, CDER, FDA

**Kui Yang, PhD**

Senior Research Scientist, DPQR II, OPQR, OPQ, CDER, FDA

**Hobart (Bart) Rogers, PharmD, PhD**

Research Officer and Reviewer, DTPM, OCP, OTS, CDER, FDA

**Sudhir Agrawal, DPhil, FRSC**

Founder and President, ARNAY Sciences; Affiliate Professor, Depart. of Medicine, University of Massachusetts Chan Medical School

**Ha-Na Lee, PhD**

Pharmaceutical Scientist, DPQR IV, OPQR, OPQ, CDER, FDA

**Filip Kolenc, MS**

Senior Global Toxicologist, Sandoz Global Development (Ljubljana, Slovenia)

**Hybrid Public Workshop**

**October 7-8, 2024**